Navigation Links
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
Date:11/6/2009

AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on November 10th, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF."

About Merriman Curhan Ford

Merriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to www.mcfco.com.

    For further information contact:
    Investor Relations
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel: (212) 845-4226
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
2. Helix BioPharma Closes Private Placement
3. Helix BioPharma Announces $13.5 Million Private Placement
4. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
6. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
7. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. Helix BioPharma to Present at the BioFinance 2009 Conference
10. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
11. Helix BioPharma Announces Q2 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and segments ... revenue. The Automatic patient billing market in Asia is ... at a developing CAGR of 7.2% from 2013 to ... Automatic patient billing market, to get an idea of ... of the segmentation of this market in the same ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
(Date:10/18/2014)... The “Human Insulin Market- by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... Kevin W. Sharer, chairman and chief executive officer of Amgen ... plan to retire from the Company at the end of ... an orderly transition process, Sharer will step down as CEO ... Company,s Board of Directors until December 31, 2012, at which ...
... OAKS, Calif., Dec. 15, 2011  Amgen (NASDAQ: AMGN ... $0.36 per share dividend for the first quarter of 2012. ... the previous two quarters. The dividend will be paid on ... the close of business on Feb. 15, 2012.  ...
... 15, 2011 Prolong Pharmaceuticals today announced ... spearhead the firms, engineering and facilities planning ...   Having previously directed the construction of the ... Grange Castle facility in Dublin, Ireland, Flachmeyer is ...
Cached Biology Technology:Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3Amgen Announces 2012 First Quarter Dividend 2Amgen Announces 2012 First Quarter Dividend 3Prolong's Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran 2
(Date:10/18/2014)... of patients with undiagnosed, suspected genetic conditions, a certain ... higher molecular diagnostic yield than traditional molecular diagnostic methods, ... The study is being released to coincide with the ... sequencing, which sequences the protein­coding region of the genome ... in a cell or organism), has been rapidly applied ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... National Oceanic and Atmospheric Administration, and the co-trustees for ... announced today they have started the injury assessment and ... a legal process to determine the type and amount ... to natural resources and their human uses as a ...
... Troy, N.Y. The purification of drug components ... is particularly true of drugs that utilize proteins, which ... impurities. Scientists within the Center for Biotechnology and Interdisciplinary ... magnetic resonance (NMR) to understand and improve an important ...
... The National Institute of Neurological Disorders and Stroke (NINDS), ... two new sites as part of the Morris K. Udall ... grants will provide a five-year investment totaling more than $16 ... for Medical Research in Manhasset, N.Y. NINDS ...
Cached Biology News:Resource restoration planning process begins for BP/Deepwater Horizon oil spill 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 3Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3NINDS awards new Udall Centers for Parkinson's Disease Research 2NINDS awards new Udall Centers for Parkinson's Disease Research 3